Take a closer look at some of our assays in our calprotectin product line. Learn more about IBDoc® and Quantum Blue®

IBDoc® Videos

BÜHLMANN - IBDoc® Swiss Medtech Award 2018

At this year’s SwissMedtech Day, BÜHLMANN was nominated to receive the Swiss Medtech Award for presenting IBDoc® to a Jury of medtech and academic reperesentatives. The jury nominated 3 projects for the Swiss Medtech Award 2018, BÜHLMANN Laboratories AG among them.

IBDoc® Self-care/Point of care Calprotectin Test: Early Value in a District General Hospital

Pearl Avery from Dorset County Hospital shows very interesting data on the clinical validity and ease of use of the IBDoc® calprotectin home test.

Interview Anke Heida, UMCG, ECCO 2017 Poster

Anke Heida from the Groningen Unversity Medical Center explains the poster published at the European Crohn’s and Colitis Congress.

Interview Caroline Bello, CHU Liege, ECCO 2017 Poster

Caroline Bello from the Liège Center Hosptial Universitaire explains the poster published at the European Crohn’s and Colitis Congress.

IBDoc® Interview with Christian Reinhard at UEGW

BÜHLMANN IBDoc® Product Manager discusses recent market experience with the first CE marked calprotectin home test at United European Gastroenterology Week 2016 in Vienna.

IBDoc® - Perspective from a Patient and Nurse

A patient and a nurse share their perspectives and experience with IBDoc® at United European Gastroenterology Week 2016 in Vienna.

IBDoc® Calprotectin Home Test from BÜHLMANN

An overview of IBDoc® as a diagnostic device for the quantitative determination of calprotectin levels in stool samples for use as a Point-of-Care test or Home Test by the patient.

Quantum Blue® Videos

BÜHLMANN Quantum Blue® fCAL Tutorial

Demonstration of CALEX® Cap extraction and quantitative fecal calprotectin measurement using the Quantum Blue® fCAL rapid test technology.

Pharmacist-led proactive therapeutic drug monitoring with infliximab (PROXIMO)

Dr. Rentsch from the Alfred Health Melbourne shows very promising data on infliximab management supported by the Quantum Blue® Infliximab rapid test and implications for therapy cost reduction.

New biosimilar of infliximab SB2 can be quantified by IXF-optimized therapeutic drug monitoring

Joana Afonso from the University of Porto presents data that confirms the validated use of the Quantum Blue® Infliximab assay to quantify the new infliximab biosimilar SB2.

Point-of-care infliximab quantification in inflammatory bowel disease in daily practice

Dr. Maria Pia Santos from the Beatriz Angelo Hospital presents data on an easy integration of the Quantum Blue® TDM rapid test in clinical routine.

Using point of care testing for infliximab and fecal calprotectin in IBD patients with secondary LOR

Dr. Afif from McGill presents a pilot study for the Quantum Blue® Infliximab rapid test application in loss of response patients.

Scientific Poster Quantum Blue® Infliximab

Thomas Schuster, PhD, presents his poster at the 11th ECCO congress about a new rapid test to measure infliximab trough levels on the BÜHLMANN Quantum Blue® Platform.

BÜHLMANN Quantum Blue® fCAL – Calprotectin POC

A brief overview of BÜHLMANN Laboratories and their product portfolio as well as an introduction to Calprotectin measurement on BÜHLMANN’s Quantum Blue® fCAL assays.

Explore  BÜHLMANN ‘s full list of video resources.

Watch more videos
Free WordPress Themes, Free Android Games

Privacy and Terms of Use!

We use cookies to understand how you use our site and to improve your experience. This includes personalizing content. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Use.